Boston Scientific Corp (BSX)
Debt-to-equity ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 21,770,000 | 20,708,000 | 20,371,000 | 19,925,000 | 19,281,000 | 18,885,000 | 18,226,000 | 17,850,000 | 17,574,000 | 17,641,000 | 17,252,000 | 16,735,000 | 16,623,000 | 16,461,000 | 15,942,000 | 15,720,000 | 15,327,000 | 15,564,000 | 15,616,000 | 13,804,000 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $21,770,000K
= 0.00
The debt-to-equity ratio for Boston Scientific Corp has consistently remained at 0.00 from March 2020 to December 2024. This indicates that the company has not utilized debt to finance its operations during this period. A low or zero debt-to-equity ratio is generally considered favorable as it suggests that the company relies more on equity financing, which may imply a lower financial risk and better financial health. However, it's also important to consider that a very low debt-to-equity ratio may limit a company's growth opportunities or indicate underutilization of debt financing that could potentially improve returns for shareholders. Overall, Boston Scientific Corp's consistent 0.00 debt-to-equity ratio reflects a conservative financial strategy with minimal reliance on debt for funding its operations.
Peer comparison
Dec 31, 2024